Poractant Alpha

Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Warnings and Precautions
  • Adverse Reactions
  • Drug Interactions
  • Dosage
  • Special Considerations

Brand Names


Austria: Curosurf; Belgium: Curosurf, Survanta; Denmark: Curosurf; Finland: Curosurf; France: Curosurf; Germany: Curosurf; Hungary: Curosurf, Survanta; Ireland: Curosurf; Italy: Curosurf; Latvia: Curosurf; Lithuania: Curosurf; Luxembourg: Curosurf; Netherlands: Curosurf; Poland: Curosurf; Portugal: Curosurf; Spain: Curosurf; Sweden: Curosurf; UK: Curosurf.

North America

USA: Curosurf.

Latin America

Argentina: Surfactante, Survanta-Abbot; Brazil: Curosurf.

Drug combinations


Poractant Alpha: extract of porcine lung containing 99% lipids, mainly phospholipids, and about 1% of hydrophobic proteins (SP-B and SP-C). CAS-129069-19-8.

Pharmacologic Category

Pulmonary Surfactants. (ATC-Code: R07AA).

Mechanism of action

Reduces surface tension at air-liquid interface of alveoli during ventilation and stabilizes alveoli against collapse at resting transpulmonary pressures.

Therapeutic use

Treatment of respiratory distress syndrome in premature infants.

Pregnancy and lactiation implications

Unlabeled use


Warnings and precautions

Pulmonary hemorrhage reported in infants who received poractant. Transient adverse effects (bradycardia, decreased oxygen saturation, hypotension, or endotracheal tube blockage) may occur. For intratracheal administration only. Hypotension, anemia, hypoglycemia, and hypothermia should be corrected before use. Produces rapid improvements in lung oxygenation and compliance.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart